Cargando…

A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases

The GM2-gangliosidoses are neurological diseases causing premature death, thus developing effective treatment protocols is urgent. GM2-gangliosidoses result from deficiency of a lysosomal enzyme β-hexosaminidase (Hex) and subsequent accumulation of GM2 gangliosides. Genetic changes in HEXA, encoding...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ou, Li, Przybilla, Michael J, Tăbăran, Alexandru-Flaviu, Overn, Paula, O’Sullivan, M. Gerard, Jiang, Xuntian, Sidhu, Rohini, Kell, Pamela J., Ory, Daniel S., Whitley, Chester B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260097/ https://www.ncbi.nlm.nih.gov/pubmed/31896760 http://dx.doi.org/10.1038/s41434-019-0120-5

Ejemplares similares

Lyso-GM2 Ganglioside: A Possible Biomarker of Tay-Sachs Disease and Sandhoff Disease
por: Kodama, Takashi, et al.
Publicado: (2011)

Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases
por: Lyn, Nicole, et al.
Publicado: (2020)

GM2-Gangliosidosis (Sandhoff and Tay Sachs disease): Diagnosis and Neuroimaging Findings (An Iranian Pediatric Case Series)
por: KARIMZADEH, Parvaneh, et al.
Publicado: (2014)

Enfermedad de Tay Sachs
por: Cibrián Cruz, José Alberto
Publicado: (1996)

Identification of mutations in HEXA and HEXB in Sandhoff and Tay-Sachs diseases: a new large deletion caused by Alu elements in HEXA
por: Dastsooz, Hassan, et al.
Publicado: (2018)

A feasibility study of mHealth and wearable technology in late onset GM2 gangliosidosis (Tay-Sachs and Sandhoff Disease)
por: Davies, Elin Haf, et al.
Publicado: (2020)

Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease
por: Vu, Mylinh, et al.
Publicado: (2018)

Investigating Immune Responses to the scAAV9-HEXM Gene Therapy Treatment in Tay–Sachs Disease and Sandhoff Disease Mouse Models
por: Kot, Shalini, et al.
Publicado: (2021)

Therapeutic Strategies For Tay-Sachs Disease
por: Picache, Jaqueline A., et al.
Publicado: (2022)

New Approaches to Tay-Sachs Disease Therapy
por: Solovyeva, Valeriya V., et al.
Publicado: (2018)

Efficient and precise generation of Tay–Sachs disease model in rabbit by prime editing system
por: Qian, Yuqiang, et al.
Publicado: (2021)

Characterization of Inducible Models of Tay-Sachs and Related Disease
por: Sargeant, Timothy J., et al.
Publicado: (2012)

Choroidal Coloboma in a Case of Tay-Sachs Disease
por: Ahmed, Nasreen Raees, et al.
Publicado: (2014)

Tay-Sachs disease: current perspectives from Australia
por: Lew, Raelia M, et al.
Publicado: (2015)

Examination of a blood-brain barrier targeting β-galactosidase-monoclonal antibody fusion protein in a murine model of GM1-gangliosidosis
por: Przybilla, Michael J., et al.
Publicado: (2021)

Prenatal diagnosis of Tay-Sachs disease: our institutional experience
por: Sheth, Jayesh, et al.
Publicado: (2014)

Neurodegeneration with Progressive Dystonia: Juvenile-Onset Tay–Sachs Disease
por: Kaur, Jasmine, et al.
Publicado: (2022)

Late-Onset Tay-Sachs Disease - expanding the clinical phenotype
por: Lefter, Stela, et al.
Publicado: (2023)

Expanding the spectrum of HEXA mutations in Indian patients with Tay–Sachs disease
por: Sheth, Jayesh, et al.
Publicado: (2014)

Telemedicine and GM-2 gangliosidosis (Tay–Sachs) disease – A new savior on the horizon during COVID-19 pandemic
por: Grover, Rohini, et al.
Publicado: (2021)

Tay-Sachs' Disease: A Study of the Symptomatology and Pathology of Three Atypical Cases
por: Torrance, Herbert Watt
Publicado: (1922)

Tay-Sachs' Disease: A Study of the Symptomatology and Pathology of Three Atypical Cases
por: Torrance, Herbert Watt
Publicado: (1922)

Tay-Sachs' Disease: A Study of the Symptomatology and Pathology of Three Atypical Cases
por: Torrance, Herbert Watt
Publicado: (1922)

Autophagic flux is impaired in the brain tissue of Tay-Sachs disease mouse model
por: Sengul, Tugce, et al.
Publicado: (2023)

Nursing Care Plan for Patients with Tay–Sachs—A Rare Paediatric Disease
por: Cortés-Martín, Jonathan, et al.
Publicado: (2023)

Knowledge and attitudes toward Tay-Sachs disease among a college student population.
por: Austein, C. F., et al.
Publicado: (1981)

Comparison of enzyme and DNA analysis in a Tay-Sachs disease carrier screening program.
por: Yoo, H. W., et al.
Publicado: (1993)

Letter response: Intra-familial phenotype variability in Late-Onset Tay-Sachs disease
por: Riboldi, Giulietta Maria, et al.
Publicado: (2023)

Identification of Novel Mutations in HEXA Gene in Children Affected with Tay Sachs Disease from India
por: Mistri, Mehul, et al.
Publicado: (2012)

Identification of novel mutations in HEXA gene in children affected with Tay-Sachs disease from India
por: Mistri, Mehul, et al.
Publicado: (2014)

Identification of deletion-duplication in HEXA gene in five children with Tay-Sachs disease from India
por: Sheth, Jayesh, et al.
Publicado: (2018)

Tay-Sachs Carrier Screening by Enzyme and Molecular Analyses in the New York City Minority Population
por: Mehta, Nikita, et al.
Publicado: (2016)

Novel HEXA variants in Korean children with Tay–Sachs disease with regression of neurodevelopment from infancy
por: Park, Ji Hong, et al.
Publicado: (2021)

Tay–Sachs disease mutations in HEXA target the α chain of hexosaminidase A to endoplasmic reticulum–associated degradation
por: Dersh, Devin, et al.
Publicado: (2016)

Diagnostic Tips from a Video Series and Literature Review of Patients with Late-Onset Tay-Sachs Disease
por: Riboldi, Giulietta Maria, et al.
Publicado: (2022)

Temporary Efficacy of Pyrimethamine in Juvenile-Onset Tay-Sachs Disease Caused by 2 Unreported HEXA Mutations in the Indian Population
por: Udwadia-Hegde, Anaita, et al.
Publicado: (2017)

Juvenile Tay Sachs Disease Due to Compound Heterozygous Mutation in Hex-A Gene, with Early Sign of Bilateral Tremors
por: Sheth, Jayesh, et al.
Publicado: (2022)

Biochemical and mutational analyses of HEXA in a cohort of Egyptian patients with infantile Tay-Sachs disease. Expansion of the mutation spectrum
por: Ibrahim, Doaa M. A., et al.
Publicado: (2023)

Effect of cyclic, low dose pyrimethamine treatment in patients with Late Onset Tay Sachs: an open label, extended pilot study
por: Osher, Etty, et al.
Publicado: (2015)

Neuraminidase-1 contributes significantly to the degradation of neuronal B-series gangliosides but not to the bypass of the catabolic block in Tay–Sachs mouse models
por: Timur, Z.K., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_r0ojtsn7n55pqihc2s0l9vgces